Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 16/20 | 0.40 |
| ▸ | BRAF | P15056 | 15/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395025 | 0.92 | FLT3 (0.38) | NTRK1NTRK3 | |
| SCHEMBL399113 | 0.87 | NTRK1 (0.51) | NTRK1NTRK3NTRK2RAF1 | |
| SCHEMBL393968 | 0.86 | NTRK1 (0.44) | NTRK1NTRK3NTRK2RAF1 | |
| SCHEMBL394096 | 0.86 | NTRK1 (0.56) | NTRK1NTRK3NTRK2RAF1 | |
| SCHEMBL394130 | 0.85 | NTRK1 (0.56) | NTRK1NTRK3NTRK2RAF1 | |
| SCHEMBL395051 | 0.84 | NTRK1 (0.45) | NTRK1NTRK3NTRK2RAF1BRAF | |
| SCHEMBL397179 | 0.82 | NTRK1 (0.48) | NTRK1NTRK3NTRK2RAF1BRAF | |
| SCHEMBL396227 | 0.79 | NTRK1 (0.45) | NTRK1NTRK3NTRK2RAF1BRAF | |
| SCHEMBL393780 | 0.79 | NTRK1 (0.52) | NTRK1NTRK3NTRK2RAF1 | |
| SCHEMBL396735 | 0.78 | NTRK1 (0.37) | NTRK1NTRK3NTRK2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |